This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Free Whitepaper How value-based care is reshaping the life sciences This free whitepaper examines the benefits of value-based care (VBC) and how this translates into the wider life-sciences landscape. AI models can predict molecular interactions and assist in designing novel compounds tailored to specific therapeutic goals.
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular dystrophy (DMD) in children. July 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook MP1032 is intended for treating Duchenne muscular dystrophy.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? compound annual growth rate (CAGR) is largely attributed to the launch of novel biologics and small molecules targeting multiple inflammatory pathways beyond TNF-alpha inhibition.
Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Juvenescence CBE and CEO Dr Richard Marshall stated: “We are delighted to welcome the Ro5 team and the company’s capabilities into Juvenescence.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Go deeper with GlobalData Reports LOA and PTSR Model - Delgocitinib in Psoriasis Reports LOA and PTSR Model - Deucravacitinib in Psoriatic Arthritis Data Insights The gold standard of business intelligence.
Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.
These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026.
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Give your business an edge with our leading industry insights.
According to GlobalData’s recent report, The State of the Biopharmaceutical Industry 2025 – Mid-Year Update, the global CGT market is estimated to be worth $79.3bn by 2030, with a 40% compound annual growth rate (CAGR). And as the number of applications for CGTs continue to grow, in the future no indication is off the table.
These tools enable the exploration of a digital library with over one trillion potential peptide compounds, streamlining the early drug discovery process. By GlobalData Learn more about Strategic Intelligence BioDuro’s role in the partnership is to leverage its synthesis capability for producing several peptide compounds in parallel.
It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. Give your business an edge with our leading industry insights.
Tariffs and trade disputes are further compounding this challenge, affecting the cost structure of pharma businesses. The complexity of customs regulations also means lead times for shipping protract, which can have a negative impact on clinical trials and product availability.
The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed. How will RFK Jr’s American dream for vaccines play out?
Reports Contract Injectable Packaging Trends in the Bio/Pharma Industry Data Insights The gold standard of business intelligence. The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. Further supporting buildings will have storage spaces, laboratories and offices.
CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. Give your business an edge with our leading industry insights.
Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide, an active ingredient in its weight-loss and diabetes drugs, Wegovy and Ozempic, respectively. The FDA has issued several alerts, including one on 29 July, warning about the dangers of these knockoff drugs.
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.
In March 2025, Novo Nordisk discounted the cost of all doses to $499 per month to competitively price its prized asset against cheaper compounded alternatives. Compounded semaglutide is a personalised weight loss medicine, which is chemically identical to branded alternatives.
By GlobalData Learn more about Strategic Intelligence Lower sales have not solely been caused by Eli Lilly – the rise in compounded semaglutide has been a big cause of concern for Novo Nordisk. The company has maintained that continued compounding is unlawful and unsafe. Stay proactive with real-time data and expert analysis.
The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is poised to grow at a compound annual growth rate of 5.3% Credit: Vitalii Vodolazskyi via Shutterstock. billion in 2024 to $10.3 Give your business an edge with our leading industry insights.
The pulmonary arterial hypertension (PAH) market is forecast to grow at a compound annual growth rate (CAGR) of 2.0% Symptoms such as fatigue, breathlessness, and chest pain are frequently misattributed to more common conditions, delaying intervention and compounding disease burden. Credit: Green Apple via Shutterstock.
By GlobalData Learn more about Strategic Intelligence Lower sales have not solely been caused by Eli Lilly – the rise in compounded semaglutide has eroded market share for Novo Nordisk. The company has maintained that continued compounding is unlawful and unsafe. Give your business an edge with our leading industry insights.
Ross Law July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The global oncology market is set to grow at a compound annual growth rate (CAGR) of 24.5%. How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E.
Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. How does bioavailability play a role in biopharmaceutics? Now fraction absorbed and bioavailability are often confused and used interchangeably.
Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. EFPIA WhitePaper on Circular Economy, June 2020. Recycling of medical plastics.
Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a whitepaper describing the content and format of an improved Module 2. The results of the risk assessment are used to define experiments.
Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a whitepaper describing the content and format of an improved Module 2. The results of the risk assessment are used to define experiments.
According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.
4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content